Kawin Technology was founded


Kawin Technology acquired Qin-Takeda Pharmaceutical.


Kawin Technology completed shareholder restructuring.
Launched a new product - compound glycyrrhizin capsule. 


Formed strategic partnership with Legend Capital.
Dr. Desheng Zhou, CEO, was enrolled into the Beijing “High-end Leading Talents Program”.
Dr. Hai Pan , VP of R&D, was enrolled into the Beijing “High-end Leading Talents Program” and “Overseas High-end Talents Program”.


Formed a strategic partnership with Haitong Capital and Cybernaut.
Initiated the construction of a brand new 2000-sqm pilot production center.


Dr. Hai Pan, VP of R&D, was nominated as China’s national “Recruitment Plan of Global Experts”, a prestigious program for overseas talents.
Launched a new product– recombinant human interferon alfa-2b effervescent tablet, China’s first-ever commercialized interferon product in this dosage form.


Certified as "Beijing Patent Demonstration Unit".
Be the first sponsor of generic Sofosbuvir trial in China.
Applied an IND for KW-136 with independent intellectual property rights.
Selected as "Beijing Biomedical Industry Crossing Development Project (G20 Project)".
Enrolled in "Beijing Biopharmaceutical Industry Breakthrough Development Project(G20 Project)".
Established "Beijing municipal International Scientific & Technological collabration Base –Preventative & Therapeutic New Drug of Liver Disease."


Dr. Zhou Desheng was nominated as Innovative Entrepreneurial Talent of Ministry of Science and Technology of the People’s Republic of China.
Certified by Colombian INVIMA GMP.
Introduced Eli Lilly Strategic Investment.
Invested GinkgoPharma(Suzhou)Co., Ltd. 


Dr. Zhou Desheng enrolled in the second batch of the national "Million Talents Plan".
China's first generic sofosbuvir raw materials and tablets were granted clinical trial approval.
The investigative new drug KW-136 with independent intellectual property rights granted CTA.
Established “Beijing Municipal Engineering Laboratory of Liver Disease Therapeutic Drug Research”.


Submission of the first China’s generic sofosbuvir tablet for ANDA
Submission of generic pirfenidone tablet for ANDA
Strategic partnership with Gaolin Capital
Designation of Beijing BDA Innovation Workshop
GMP recertification of multiple formulations at No. 7 Rongchang Street East site
Enrolled in the first batch of the 13th Five-Year Plan "Beijing Biopharmaceutical Industry Breakthrough Development Project (G20 Project)". 


Peginterferon alfacon-2 Injection approved by NMPA
NDA Submission of coblopasvir
Ukrainian GMP recertification of manufacture facility at No.7 Rongchang Street east
GMP recertification of multiple products and formulations
National High-tech Enterprise recertification


Pirfenidone tablets, indicated for Idiopathic pulmonary fibrosis (IPF) treatment, obtained marketing authorization
Benchmarking Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of China
"2019 China Top 100 Pharmaceutical Innovative Enterprises" 


Launch of 1st local pan-genotype HCV full oral drug combo
Class 1 New Drug Coblopasvir Hydrochloride Capsules included the National Reimbursement Drug List (NRDL)
Sofosbuvir tablets and pirfenidone tablets included in “List of launched drug in China”
"2020 China Top 100 Pharmaceutical Innovative Enterprises" 


IPO in Shanghai Stock Exchange STAR Market 

+86 10 87120888